Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro

Hao,Shuhong; Du,Xiaoyuan; Song,Yang; Ren,Ming; Yang,Qiwei; Wang,Ao; Wang,Qingyu; Zhao,Haiyue; Du,Zhenwu; Zhang,Guizhen

doi:10.3892/ol.2018.8148

Targeted gene therapy of the HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of human non-small cell lung cancer in vitro

Authors:
- Shuhong Hao
- Xiaoyuan Du
- Yang Song
- Ming Ren
- Qiwei Yang
- Ao Wang
- Qingyu Wang
- Haiyue Zhao
- Zhenwu Du
- Guizhen Zhang
View Affiliations

Affiliations: Department of Hematology and Oncology, The Second Clinical College, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathology, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Orthopedics, The Second Clinical College, Jilin University, Changchun, Jilin 130021, P.R. China, The Center of Molecular Diagnosis and Cellular Treatment for Metabolic Bone Diseases, Changchun, Jilin 130041, P.R. China, Research Center, The Second Clinical College, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: March 1, 2018 https://doi.org/10.3892/ol.2018.8148
Pages: 6503-6512

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of lung cancer and lung cancer-associated mortality have markedly increased worldwide, and gene‑targeted therapy has emerged as a promising treatment strategy. The present study aimed to explore the targeted antitumor effect of the herpes simplex virus‑thymidine kinase/human interleukin‑12 (HSV‑TK/hIL‑12) fusion gene regulated by the human secretory leukocyte protease inhibitor (hSLPI) promoter of human non‑small cell lung cancer (hNSCLC). There were four recombinant eukaryotic expression vectors: pcDNA3.1‑CMV‑TK, pcDNA3.1‑CMV‑TK/hIL‑12, pcDNA3.1‑phSLP‑TK and pcDNA3.1-phSLP-TK/hIL-12. These were constructed and transfected into the A549, SPC‑A1 and HepG2 cell lines in vitro. The expression of the HSV‑TK/hIL‑12 fusion gene was detected with reverse transcription‑polymerase chain reaction (RT‑PCR), and the content of hIL‑12 was measured using an ELISA. The antitumor effect of the fusion gene on the A549, SPC‑A1 and HepG2 cell lines was determined using an MTT assay. Analysis of the experimental data demonstrated that genes regulated by the cytomegalovirus promoter were expressed at the same level in three different tumor cell lines. Genes regulated by the hSLPI promoter were expressed in the A549 and SPC‑A1 cell lines, but not in the HepG2 cell line. Coincidentally, the hIL‑12 expression levels were similar to those observed in previous RT‑PCR findings. In the Pcmv‑TK/Pcmv‑TK‑hIL‑12 group for all three cell lines, as well as in the PSLPI‑TK/PSLPI‑TK‑hIL‑12 group for the A549 and SPC‑A1 cell lines, the cell survival rate declined significantly and the fusion gene transfection group indicated a lower cell survival rate, when compared with single gene transfection group. The present study indicated that the fusion gene regulated by the hSLPI promoter had a targeted antitumor effect on hNSCLC, and that the combined suicide gene and immune gene therapy had a stronger antitumor effect, compared with single gene therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, Asai G, Endo M and Takahashi T: Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 98:226–230. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y and Du J: High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer. 49:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
4	Sun S, Schiller JH, Spinola M and Minna JD: New molecularly targeted therapies for lung cancer. J Clin Invest. 117:2740–2750. 2007. View Article : Google Scholar : PubMed/NCBI
5	Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, Freitag L, Zarogoulidis K and Malecki M: Suicide gene therapy for cancer-current strategies. J Genet Syndr Gene Ther. 4:168492013.PubMed/NCBI
6	Lv SQ, Zhang KB, Zhang EE, Gao FY, Yin CL, Huang CJ, He JQ and Yang H: Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit. 15:BR13–BR20. 2009.PubMed/NCBI
7	Finocchiaro LM, Riveros MD and Glikin GC: Cytokine-enhanced vaccine and suicide gene therapy as adjuvant treatments of metastatic melanoma in a horse. Vet Rec. 164:278–279. 2009. View Article : Google Scholar : PubMed/NCBI
8	Ju DW, Yang Y, Tao Q, Song WG, He L, Chen G, Gu S, Ting CC and Cao X: Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. Gene Ther. 7:1672–1679. 2000. View Article : Google Scholar : PubMed/NCBI
9	Drozdzik M, Qian C, Xie X, Peng D, Bilbao R, Mazzolini G and Prieto J: Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol. 32:279–286. 2000. View Article : Google Scholar : PubMed/NCBI
10	Warren P, Song W, Holle E, Holmes L, Wei Y, Li J, Wagner T and Yu X: Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice. Anticancer Res. 22:599–604. 2002.PubMed/NCBI
11	Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, et al: Tumor-specific CD8⁺ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725–6234. 2010. View Article : Google Scholar : PubMed/NCBI
12	Terao S, Shirakawa T, Goda K, Kamidono S, Fujisawa M and Gotoh A: Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model. Anticancer Res. 25:2757–2760. 2005.PubMed/NCBI
13	Hall SJ, Canfield SE, Yan Y, Hassen W, Selleck WA and Chen SH: A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL12 gene therapies in experimental prostate cancer. Gene Ther. 9:511–517. 2002. View Article : Google Scholar : PubMed/NCBI
14	Nasu Y, Bangma CH, Hull GW, Yang G, Wang J, Shimura S, McCurdy MA, Ebara S, Lee HM, Timme TL and Thompson TC: Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis. 4:44–55. 2001. View Article : Google Scholar : PubMed/NCBI
15	Fogar P, Greco E, Basso D, Habeler W, Navaglia F, Zambon CF, Tormen D, Gallo N, Cecchetto A, Plebani M and Pedrazzoli S: Suicide gene therapy with HSV-TK in pancreatic cancer has no effect in vivo in a mouse model. Eur J Surg Oncol. 29:721–730. 2003. View Article : Google Scholar : PubMed/NCBI
16	Okada Y, Okada N, Mizuguchi H, Hayakawa T, Nakagawa S and Mayumi T: Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther. 12:608–616. 2005. View Article : Google Scholar : PubMed/NCBI
17	Schoensiegel F, Paschen A, Sieger S, Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D and Haberkorn U: MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther. 11:408–418. 2004. View Article : Google Scholar : PubMed/NCBI
18	Curvelo JA, Barreto AL, Portela MB, Alviano DS, Holandino C, Souto-Padrón T and Soares RM: Effect of the secretory leucocyte proteinase inhibitor (SLPI) on Candida albicans biologicalprocesses: A therapeutic alternative? Arch Oral Biol. 59:928–937. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I and Mitsuhashi H: Increased secretory leukoprotease inhibitor in patients with non-small cell lung carcinoma. Cancer. 89:1448–1456. 2000. View Article : Google Scholar : PubMed/NCBI
20	Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie X, Tang Z and Jiang X: Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells. Clin Transl Oncol. 17:314–321. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hough CD, Cho KR, Zonderman AB, Schwartz DR and Morin PJ: Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61:3869–3876. 2001.PubMed/NCBI
22	Franken C, Meijer CJ and Dijkman JH: Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem. 37:493–498. 1989. View Article : Google Scholar : PubMed/NCBI
23	Chen PJ, Kuo MY, Chen ML, Tu SJ, Chiu MN, Wu HL, Hsu HC and Chen DS: Continuous expression and replication of the hepatitis delta virus genome in Hep G2 hepatoblastoma cells transfected with cloned viral DNA. Proc Natl Acad Sci USA. 87:5253–5257. 1990. View Article : Google Scholar : PubMed/NCBI
24	Alexandrova R: Experimental strategies in gene therapy of cancer. J Buon. 14:S23–S32. 2009.PubMed/NCBI
25	Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML and Naomoto Y: Adenovirus-mediated cancer gene therapy and virotherapy (Review). Int J Mol Med. 25:3–10. 2010.PubMed/NCBI
26	Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D and Fisher PB: Gene therapies for cancer: Strategies, challenges and successes. J Cell Physiol. 230:259–271. 2015. View Article : Google Scholar : PubMed/NCBI
27	Nettelbeck DM, Jérôme V and Müller R: Gene therapy: Designer promoters for tumour targeting. Trends Genet. 16:174–181. 2000. View Article : Google Scholar : PubMed/NCBI
28	Luo XR, Li JS, Niu Y and Miao L: Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell. Mol Biol Rep. 38:1201–1207. 2011. View Article : Google Scholar : PubMed/NCBI
29	Teimoori-Toolabi L, Azadmanesh K, Amanzadeh A and Zeinali S: Selective suicide gene therapy of colon cancer exploiting the urokinase plasminogen activator receptor promoter. BioDrugs. 24:131–146. 2010. View Article : Google Scholar : PubMed/NCBI
30	Nakamura K, Takamoto N, Hongo A, Kodama J, Abrzua F, Nasu Y, Kumon H and Hiramatsu Y: Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer. Oncol Rep. 19:1085–1091. 2008.PubMed/NCBI
31	Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A and Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol. 96:516–519. 2005. View Article : Google Scholar : PubMed/NCBI
32	Robertson MW III, Wang M, Siegal GP, Rosenfeld M, Ashford RS II, Alvarez RD, Garver RI and Curiel DT: Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther. 5:331–336. 1998.PubMed/NCBI
33	Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, et al: The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med. 5:300–310. 2003. View Article : Google Scholar : PubMed/NCBI
34	Maemondo M, Saijo Y, Narumi K, Kikuchi T, Usui K, Tazawa R, Matsumoto K, Nakamura T, Sasaki K, Takahashi M, et al: Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res. 64:4611–4620. 2004. View Article : Google Scholar : PubMed/NCBI
35	Uchibori R, Okada T, Ito T, Urabe M, Mizukami H, Kume A and Ozawa K: Retroviral vector-producting mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med. 11:373–381. 2009. View Article : Google Scholar : PubMed/NCBI
36	Nanni P, Rossil L, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP and Lollini PL: Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 58:1225–1230. 1998.PubMed/NCBI
37	Loskog A, Björkland A, Brown MP, Korsgren O, Malmström PU and Tötterman TH: Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J Urol. 166:1093–1097. 2001. View Article : Google Scholar : PubMed/NCBI
38	Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M and Dörken B: Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther. 4:9–16. 1997.PubMed/NCBI
39	van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, van der Eb AJ, Rinkes Borel IH, van de Velde CJ and Hoeben RC: Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virusthymidine kinase gene and ganciclovir administration. Gene Ther. 5:451–458. 1998. View Article : Google Scholar : PubMed/NCBI
40	Larocca C and Schlom J: Viral vector-based therapeutic cancer vaccines. Cancer J. 17:359–371. 2011. View Article : Google Scholar : PubMed/NCBI
41	Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al: A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther. 18:852–860. 2010. View Article : Google Scholar : PubMed/NCBI
42	Ring C, Harris JD, Hurst HC and Lemoine NR: Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the promoter. Gene Ther. 3:1094–1103. 1996.PubMed/NCBI
43	Ejeskär K, Fransson S, Zaibak F and Ioannou PA: Method for efficient transfection of in vitro-transcribed mRNA into SK-N-AS and HEK293 cells: Difference in the toxicity of nuclear EGFP compared to cytoplasmic EGFP. Int J Mol Med. 17:1011–1016. 2006.PubMed/NCBI
44	Kamaci N, Emnacar T, Karakas N, Arikan G, Tsutsui K and Isik S: Selective silencing of DNA topoisomerase IIβ in human mesenchymal stem cells by siRNAs (small interfering RNAs). Cell Biol Int Rep (2010). 18:e000102011.PubMed/NCBI
45	Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ and Ciccarone VC: Advanced transfection with Lipofectamine 2000 reagent: Primary neurons, siRNA, and high-throughput applications. Methods. 33:95–103. 2004. View Article : Google Scholar : PubMed/NCBI
46	Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:5276–2581. 1986.PubMed/NCBI
47	Ambade AV, Joshi GV and Mulherkar R: Effect of suicide gene therapy in combination with immunotherapy on antitumour immuneresponse & tumour regression in a xenograft mouse model for head & neck squamous cellcarcinoma. Indian J Med Res. 132:415–422. 2010.PubMed/NCBI
48	Rodriguez SS, Castro MG, Brown OA, Goya RG and Console GM: Gene therapy for the treatment of pituitary tumors. Expert Rev Endocrinol Metab. 4:359–370. 2009. View Article : Google Scholar : PubMed/NCBI
49	Ramesh R, Marrogi AJ, Munshi A, Abboud CN and Freeman SM: In vivo analysis of the ‘bystander effect’: A cytokine cascade. Exp Hamatol. 24:829–838. 1996.
50	Wei MX, Bougnoux P, Sacré-Salem B, Peyrat MB, Lhuillery C, Salzmann JL and Klatzmann D: Suicide gene therapy of chemically induced mammary tumor in rat: Efficacy and distant bystander effect. Cancer Res. 58:3529–3532. 1998.PubMed/NCBI
51	Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D and Klatzmann D: A ‘distant’ bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 8:1807–1814. 1997. View Article : Google Scholar : PubMed/NCBI
52	van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF and Hospers GA: Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther. 2:307–322. 2002. View Article : Google Scholar : PubMed/NCBI